HAGE (DDX43) is a biomarker for poor prognosis and a predictor of chemotherapy response in breast cancer

Background:HAGE protein is a known immunogenic cancer-specific antigen.Methods:The biological, prognostic and predictive values of HAGE expression was studied using immunohistochemistry in three cohorts of patients with BC (n=2147): early primary (EP-BC; n=1676); primary oestrogen receptor-negative (PER-BC; n=275) treated with adjuvant anthracycline-combination therapies (Adjuvant-ACT); and primary locally advanced disease (PLA-BC) who received neo-adjuvant anthracycline-combination therapies (Neo-adjuvant-ACT; n=196). The relationship between HAGE expression and the tumour-infiltrating lymphocytes (TILs) in matched prechemotherapy and postchemotherapy samples were investigated.Results:Eight percent of patients with EP-BC exhibited high HAGE expression (HAGE+) and was associated with aggressive clinico-pathological features (Ps<0.01). Furthermore, HAGE+expression was associated with poor prognosis in both univariate and multivariate analysis (Ps<0.001). Patients with HAGE+did not benefit from hormonal therapy in high-risk ER-positive disease. HAGE+and TILs were found to be independent predictors for pathological complete response to neoadjuvant-ACT; P<0.001. A statistically significant loss of HAGE expression following neoadjuvant-ACT was found (P=0.000001), and progression-free survival was worse in those patients who had HAGE+residual disease (P=0.0003).Conclusions:This is the first report to show HAGE to be a potential prognostic marker and a predictor of response to ACT in patients with BC.

[1]  M. Dowsett,et al.  American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of oncology practice.

[2]  K. Pantel,et al.  MAGE-A gene expression pattern in primary breast cancer. , 2001, Cancer research.

[3]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Dry,et al.  The clinical significance of MAGEA3 expression in pancreatic cancer , 2006, International journal of cancer.

[5]  E. Sabo,et al.  Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2007, Archives of pathology & laboratory medicine.

[7]  M. Cravo,et al.  Global DNA hypomethylation in breast carcinoma , 1999, Cancer.

[8]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Grande,et al.  Involvement of RNA helicases p68 and p72 in colon cancer. , 2007, Cancer research.

[10]  R. Rees,et al.  HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides , 2007, Cancer Immunology, Immunotherapy.

[11]  G. Ball,et al.  Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer , 2010, The Journal of pathology.

[12]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.

[13]  N. Harbeck,et al.  Personalized treatment of early-stage breast cancer: present concepts and future directions. , 2010, Cancer treatment reviews.

[14]  S. Pinder,et al.  Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up , 1994, Histopathology.

[15]  B. Czepulkowski,et al.  Frequent expression of HAGE in presentation chronic myeloid leukaemias , 2002, Leukemia.

[16]  R. Rees,et al.  The Helicase HAGE Expressed by Malignant Melanoma-Initiating Cells Is Required for Tumor Cell Proliferation in Vivo* , 2012, The Journal of Biological Chemistry.

[17]  Early Breast Cancer Trialists' Collaborative Group.  Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials , 2008, The Lancet.

[18]  M. Ehrlich,et al.  Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. , 1999, Mutation research.

[19]  P. Coulie,et al.  Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen , 2005, The Journal of experimental medicine.

[20]  R. Rees,et al.  HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers. , 2010, Cancer immunity.

[21]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[22]  H. Moch,et al.  Frequent expression of the novel cancer testis antigen MAGE‐C2/CT‐10 in hepatocellular carcinoma , 2009, International journal of cancer.

[23]  I. Ellis,et al.  The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers , 2010, The Journal of pathology.

[24]  D. Heimburger,et al.  Altered global methylation of DNA: an epigenetic difference in susceptibility for lung cancer is associated with its progression. , 2001, Human pathology.

[25]  Xiaochu Yan,et al.  High Expression of Testes-Specific Protease 50 Is Associated with Poor Prognosis in Colorectal Carcinoma , 2011, PloS one.

[26]  R. Peto.  EARLY BREAST-CANCER TRIALISTS COLLABORATION , 1987 .

[27]  L. Goldstein,et al.  Optimizing chemotherapy regimens for patients with early-stage breast cancer. , 2010, Clinical breast cancer.

[28]  J. Mackey,et al.  DEAD box 1: a novel and independent prognostic marker for early recurrence in breast cancer , 2011, Breast Cancer Research and Treatment.

[29]  Simak Ali,et al.  The DEAD box protein p72 regulates ERα-/Estrogen-dependent transcription and cell growth, and is associated with improved survival in ERα positive breast cancer , 2009, Oncogene.

[30]  T. Boon,et al.  Identification on a human sarcoma of two new genes with tumor-specific expression. , 2000, Cancer research.

[31]  S. Glück,et al.  Improving outcomes in early-stage breast cancer. , 2010, Oncology.

[32]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[33]  A. Simpson,et al.  Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers , 2011, PloS one.

[34]  D. Lane,et al.  Identification of a putative RNA helicase in E.coli. , 1990, Nucleic acids research.

[35]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[36]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Mazumdar,et al.  Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. , 2007, Cancer immunity.

[38]  Yao-Tseng Chen,et al.  Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. , 2001, Cancer research.

[39]  Zhi-Ren Liu,et al.  Phosphorylations of DEAD Box p68 RNA Helicase Are Associated with Cancer Development and Cell Proliferation , 2005, Molecular Cancer Research.

[40]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. , 1999, Critical reviews in oncology/hematology.

[41]  A. Giuliano,et al.  Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma , 1994, Cancer.

[42]  Francisco Cervantes,et al.  Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. , 2007, Haematologica.